Abbvie Inc Stock Price, News & Analysis

AbbVie (NYSE: ABBV) reported topline Phase 3b/4 SELECT-SWITCH results showing RINVOQ (upadacitinib) 15 mg once daily was superior to HUMIRA (adalimumab) 40 mg biweekly at Week 12 in adults with moderate-to-severe rheumatoid arthritis who failed a prior TNF inhibitor.

Key results: 43.3% on upadacitinib achieved low disease activity (DAS28-CRP≤3.2) vs 22.4% on adalimumab (p<0.001); 28.4% vs 14.5% achieved remission (DAS28-CRP<2.6) (p<0.001). Safety was consistent with prior studies with no new risks identified in the 12-week period.

AbbVie (NYSE: ABBV) completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, on Oct 17, 2025.

Bretisilocin is described as a novel, short-acting 5-HT2A receptor agonist and serotonin releaser currently in Phase 2 clinical development for moderate-to-severe major depressive disorder (MDD). AbbVie said the compound is next‑generation and designed to address development challenges seen with classic psychedelic therapies, and that the company plans to accelerate its development within AbbVie’s psychiatry pipeline.

AbbVie (NYSE: ABBV) announced that on October 13, 2025 the U.S. FDA approved a supplemental NDA updating the indication for RINVOQ (upadacitinib) to treat adults with moderately to severely active ulcerative colitis and Crohn's disease.

The updated label permits RINVOQ to be used prior to tumor necrosis factor (TNF) blockers for patients for whom TNF blockers are clinically inadvisable and allows use after the patient has received at least one approved systemic therapy. The change expands prescribing options for physicians treating inflammatory bowel disease.

The release reiterates RINVOQ safety considerations, including risks of serious infections, increased risk of death and major cardiovascular events in people age 50+ with ≥1 heart disease risk factor, certain cancers, blood clots, serious allergic reactions, and gastrointestinal tears.

AbbVie (NYSE: ABBV) will present new clinical data at the ESMO 2025 Congress (October 17–21, 2025) on its antibody-drug conjugate portfolio, highlighting telisotuzumab adizutecan (Temab-A), ABBV-706, and other ADC programs.

Key findings include Temab-A: ORR 46% in 100 MET-amplified solid tumor patients (NSCLC 69%, GEA 71%); Temab-A+bevacizumab ORR 26.7% in heavily pretreated CRC vs 0% with trifluridine/tipiracil+bev; Temab-A in PDAC ORR 24% overall (40% in prior gemcitabine–nab-paclitaxel subgroup). Observed grade ≥3 TEAEs included anemia and neutropenia across studies. ABBV-706 data show ctDNA clearance linked to higher PFS and OS and support ongoing first-line combination study.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced SkinMedica's reimagined packaging and the new HA5® Hydra Collagen Water Burst Moisturizer on Oct 9, 2025. The redesign features a refreshed logo, luxe copper accents, intuitive navigation, and sustainability upgrades: 90% of packaging components by weight recyclable, 100% of secondary cartons recyclable, and a 71% reduction in landfill waste (~550,000 lbs annually). Product launches include HA5 moisturizer (up to 24-hour hydration, 25% moisture boost after one application), TNS Advanced+ serum dual-pump, and phased rollout across the portfolio over the next year. HA5 moisturizer retails at $78 and is available online and via licensed physicians and spas.

AbbVie (NYSE: ABBV) reported positive topline results from the Phase 2 ELATE trial of onabotulinumtoxinA (BOTOX) for upper limb essential tremor on Oct 6, 2025. The study met its primary endpoint at week 18: TREDS-R total unilateral score change was -2.61 for onabotulinumtoxinA vs -1.61 for placebo (p=0.029). The trial also met all six secondary endpoints. Safety was consistent with the known profile of onabotulinumtoxinA; the most common adverse event was localized, mostly mild-to-moderate muscular weakness (24.5% on active vs 2.3% placebo). Results will be presented at the International Congress of Parkinson's Disease and Movement Disorders on Oct 8, 2025. BOTOX for essential tremor is not approved by the FDA or other regulators.

AbbVie (NYSE:ABBV) has scheduled its third-quarter 2025 financial results announcement for Friday, October 31, 2025, before market opening. The company will conduct a live earnings conference call at 8 a.m. Central time.

Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the presentation will be made available later the same day.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has secured a supplier agreement with Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement provides Vizient's network, which represents over 50% of U.S. healthcare organizations, enhanced access to Natrelle®'s comprehensive breast implant line featuring more than 300 implant options.

The partnership offers Vizient clients competitive pricing, simplified procurement, improved operational efficiency, and direct support from Natrelle®'s sales and technical teams. Natrelle®, currently the #1 selected breast implant by plastic surgeons, brings a 50-year legacy of excellence in breast reconstruction and augmentation solutions.

AbbVie (NYSE:ABBV) has initiated construction on a $70 million expansion at its AbbVie Bioresearch Center in Worcester, Massachusetts. The expansion is part of AbbVie's broader $10 billion U.S. investment commitment to enhance biologics manufacturing capabilities and capacity.

The project includes new biologics manufacturing areas and a three-story building for laboratory, warehouse, and office space. This investment will facilitate the transfer of select oncology products from Europe to the U.S. and support the production of current and next-generation oncology and immunology medicines. The expansion will create new jobs, adding to AbbVie's existing 28,000 U.S. employees, including over 2,000 in Massachusetts.